Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 26:13:6689-6703.
doi: 10.2147/CMAR.S322411. eCollection 2021.

Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice

Agustín Falco  1 , Thiago Bueno de Oliveira  2 , Jon Cacicedo  3 , Aylen Vanessa Ospina  4 , Miguel Ángel Ticona  5 , Héctor Galindo  6 , Marcos David Pereira  7 , José Luis Aguilar-Ponce  8 , Antonio Rueda-Domínguez  9 , Tannia Soria  10 , Miren Taberna  11 , Lara Iglesias  12 , Taysser Sowley  13 , Ricard Mesía  14 ; TTCC group (Spanish Group for the Treatment of the Head and Neck Cancer)
Affiliations
Review

Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice

Agustín Falco et al. Cancer Manag Res. .

Abstract

Cisplatin is the standard of treatment for squamous cell carcinoma of the head and neck (SCCHN) that has demonstrated efficacy, either in locally advanced disease when combined with radiotherapy at high doses, or in metastatic/recurrent disease when combined with other agents. However, the usual toxicities related to cisplatin, such as neurotoxicity, nephrotoxicity, ototoxicity, and hematologic toxicities, especially when high doses have been administered, have important implications in the patients' quality of life. The decision to administer cisplatin depends on several patient factors, such as age, performance status, weight loss, comorbidities, previous toxicities, chronic viral infection, or even the current SARS-CoV-2 pandemic. In order to establish recommendations for the management of patients with SCCHN, a group of experts in medical and radiation oncology from Spain and Latin-American discussed how to identify patients who are not candidates for cisplatin to offer them the most suitable therapeutic alternative.

Keywords: age; cisplatin; comorbidities; contraindication; frailty; toxicity.

PubMed Disclaimer

Conflict of interest statement

None of the authors were compensated for this manuscript, but have received consultancy fees from the “TTCC-Grupo Español de Tratamiento de Tumores de Cabeza y Cuello” for the development of this consensus. Ricard Mesía MD, PhD has received support for his advisory work from pharmaceutical companies including Merck, MSD, BMS, AstraZeneca, and Roche. He has also received fees for Speakers’ bureau from Merck, MSD, Roche, and BMS. Agustín Falco MD has received support for his advisory work from Merck, MSD, Biotoscana, Bayer and BMS. He has also received Speakers’ bureau fees from Merck, MSD, BMS, Varifarma, and Raffo. Thiago Bueno de Oliveira MD, PhD has received support for his advisory work from pharmaceutical companies including Merck Serono, Merck Sharp Dohme, MSD, BMS, Janssen, AstraZeneca, and Bayer. He has also received fees for Speakers’ bureau from Merck, MSD, and BMS. Aylen Vanessa Ospina MD has received support for advisory work from pharmaceutical companies including Merck, MSD, BMS and Roche. She has also received fees for Speakers’ bureau from MSD, Roche and BMS. Miguel Ángel Ticona MD has received support for his advisory work from Merck, MSD, Roche, Tecnofarma, Bayer, and Biotoscana. He has also received fees for Speaker’s bureau from Merck, MSD, Tecnofarma, Bayer, and Takeda. Marcos David Pereira MD has received support for his advisory work from Merck, MSD, and Novartis, and Speakers’ bureau fees from Merck and MSD. Antonio Rueda-Domínguez MD has received lectures and/or advisory fees from Merck, MSD, BMS, Takeda, Gilead, Novartis, Kern Pharma, and Roche. Tannia Soria MD has received consultancy honoraria from Merck Ca, Abbott, Pfizer, MSD, Medicamenta, Roche, and Boehringer-Ingelheim. She has also received clinical studies fees from Roche, Tesaro, MSD, and Lilly. She has also received fees for her advisory work from Roche, Merck Ca, Pfizer, Novartis, Boehringer-Ingelheim, AstraZeneca, and MSD. Miren Taberna MD, PhD has received support for her advisory work from pharmaceutical companies including Merck, MSD, and Nanobiotics. She has also received fees for Speakers’ bureau from Merck, MSD, and BMS. Lara Iglesias MD has received advisory board fees from Merck, MSD, BMS, Lilly, Roche, Sanofi, and Bayer. Taysser Sowley MD has received support for her advisory work from Roche, MSD, Pfizer, Novartis, AstraZeneca, and Bayer. She has also received Speakers’ bureau fees from Roche, MSD, Novartis, AstraZeneca, and Merck. The remaining authors declare no conflicts of interest.

References

    1. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92–98. doi:10.1200/JCO.2003.01.008 - DOI - PubMed
    1. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845–852. doi:10.1200/JCO.2012.43.6097 - DOI - PMC - PubMed
    1. Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40–50. doi:10.1016/S0140-6736(18)32779-X - DOI - PMC - PubMed
    1. Vermorken JB, Mesía R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127. doi:10.1056/NEJMoa0802656 - DOI - PubMed
    1. Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, Phase 3 study. Lancet. 2019;394(10212):1915–1928. doi:10.1016/S0140-6736(19)32591-7 - DOI - PubMed